Methods for smoking cessation or alcohol cessation or other addiction cessation

• US 20070134169A1
• Filed: 12/11/2006
• Published: 06/14/2007
• Est. Priority Date: 12/11/2005
• Status: Abandoned Application

• Current Assignee: Biogenesys Incorporated
• Original Assignee: Biogenesys Incorporated
• Inventors: Rabinoff, Michael
• Application Number:
  US11/609,265
• Publication Number:
  US 20070134169A1
• Time in Patent Office: Days
• US Class Current: 424/48
• CPC Class Codes: A61K 9/0043 Nose
• CPC Class Codes: A61K 9/0058 Chewing gums non-medicinal aspects, preparing chewing gum A23G4/00; chewing gum for care of the teeth or oral cavity, e.g. with breath freshener A61Q11/00
• CPC Class Codes: A61K 9/008 comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
• CPC Class Codes: A61K 9/7023 Transdermal patches and similar drug-containing composite devices, e.g. cataplasms galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006
• CPC Class Codes: A61M 11/00 Sprayers or atomisers specially adapted for therapeutic purposes in general B05B; aerosol containers B65D83/14

Abstract

The invention is a patch or other applicator, or other method of administration, and a process to concept is to utilize patches (or other methods of delivery), that may contain nicotine in addition to, and that contain other chemicals that have been shown, or will be shown, either by subjective or objective measures, to increase “impact” (an tobacco industry term for the subjective awareness by the smoker of the drug effects of nicotine), or to increase addiction. Chemicals that decrease addiction behavior, or decrease signs and symptoms of withdrawal from the addictive substance or behavior may also be included. The claimed methods have application in the treatment of addiction to tobacco products, addiction to alcohol, and other addictions.

Claims

1. A device for treating addiction comprising:

an applicator that delivers a plurality of chemicals

2. A device according to claim 1, wherein said delivery is by one or more of a set of, oral ingestion, sublingual, via saliva, intra-muscular administration, intra-venous administration, intra-arterial administration, intra-thecal administration, trans-vaginal, trans-rectal, trans-urethral or trans-vesicular, or trans-cutaneous.

3. A device according to claim 2, in which said delivery means include one or more of a set of;

liposomal, microsomal, DNA-conjugate, RNA-conjugate, siRNA-conjugate, chemical-conjugate, viral or viral fragment CNS targeting agent;

specific CNS region targeted liposomal, microsomal, DNA-conjugate, RNA-conjugate, siRNA-conjugate, chemical-conjugate, viral or viral fragment CNS targeting agent;

or micro sized formulations.

4. A device according to claim 1, wherein said chemical include one or more of a set of acetaldehyde, acetaldehyde related compounds, formaldehyde related compounds and derivatives, isoquinolones, isoquinoxalines, tetrahydro-isoquinolones (and related compounds), 1,2,3,4-tetrahydroisoquinoline (and related compounds), 5-tetrahydroquin-oxaline, 6-tetrahydroquin-oxaline, 7-tetrahydroquin-oxaline, 8-tetrahydroquin-oxaline, 5,6,7,8-tetrahydroquin-oxaline, salsinol, tetrahydropapaveroline, pyridine, pyridine derivatives, lobeline, levulinic acid, 4-oxopentanoic acid, nicotine levulinate, 4-pentenoic acid, omega-pentadecalactone, 2,3-pentanedione, 2-pentanone, 2-pentylpyridine, pyrazine (and related compounds), vanillin, propylene glycol, naltrexone, opioid agonists, opioid antagonists, opioid partial agonists, antagonists, harman, norharman, carbolines (and related compounds), beta-carbolines (and related compounds), aromatic amines, nicotine, or nicotine related compounds.

5. A device according to claim 1, which includes a means to enhance chemicals crossing the blood brain barrier.

6. A device according to claim 5, in which said delivery means include one or more of a set of;

liposomal, microsomal, DNA-conjugate, RNA-conjugate, siRNA-conjugate, chemical-conjugate, viral or viral fragment CNS targeting agent;

specific CNS region targeted liposomal, microsomal, DNA-conjugate, RNA-conjugate, siRNA-conjugate, chemical-conjugate, viral or viral fragment CNS targeting agent;

or micro sized formulations.

7. A device according to claim 2, wherein said device is a transdermal patch.

8. A device according to claim 2, wherein said device is gum.

9. A device according to claim 2, wherein said device is an inhaler.

10. A device according to claim 2, wherein said device is a nasal spray.

19. A device according to claim 1, wherein said chemical include one or more of a set of chemical or chemicals known to decrease addiction behavior, or smoking behavior, or facilitate smoking cessation, or facilitate addiction cessation, or decrease signs and symptoms of nicotine and cigarette withdrawal, or other withdrawal, may be included in the device, including (but not limited to), clonidine, amfebutamone, mecamylamine, nortriptyline and moclobemide, dextrose, sugars, flavorants, vitamins, amino acids, minerals, other neutraceuticals, selegiline, pargyline, clorgyline, tranylcypromine, phenelzine, other inhibitors of MAO-A, other inhibitors of MAO-B, p-tyramine, serotonin, beta-phenylethylamine, or compounds related to these compounds.

11. A method of administration for treating addiction comprising:

a method of administration dosage to the body where delivery is by one or more of a set of, oral ingestion, sublingual, via saliva, intramuscular administration, intra-venous administration, intra-arterial administration, intra-thecal administration, trans-vaginal, trans-rectal, trans-urethral or trans-vesicular, or trans-cutaneous.

12. A method according to claim 11, in which said delivery means include one or more of a set of;

liposomal, microsomal, DNA-conjugate, RNA-conjugate, siRNA-conjugate, chemical-conjugate, viral or viral fragment CNS targeting agent;

specific CNS region targeted liposomal, microsomal, DNA-conjugate, RNA-conjugate, siRNA-conjugate, chemical-conjugate, viral or viral fragment CNS targeting agent;

or micro sized formulations.

13. A method according to claim 11, wherein said chemical include one or more of a set of acetaldehyde, acetaldehyde related compounds, formaldehyde related compounds and derivatives, isoquinolones, isoquinoxalines, tetrahydro-isoquinolones, (and related compounds), 1,2,3,4-tetrahydroisoquinoline (and related compounds), 5-tetrahydroquin-oxaline, 6-tetrahydroquin-oxaline, 7-tetrahydroquin-oxaline, 8-tetrahydroquin-oxaline, 5,6,7,8-tetrahydroquin-oxaline, salsinol, tetrahydropapaveroline, pyridine, pyridine derivatives, lobeline, levulinic acid, 4-oxopentanoic acid, nicotine levulinate, 4-pentenoic acid, omega-pentadecalactone, 2,3-pentanedione, 2-pentanone, 2-pentylpyridine, pyrazine (and related compounds), vanillin, propylene glycol, naltrexone, opioid agonists, opioid antagonists, opioid partial agonists, antagonists, harman, norharman, carbolines (and related compounds), beta-carbolines (and related compounds), aromatic amines, nicotine, or nicotine related compounds.

14. A method according to claim 11, which includes a means to enhance chemicals crossing the blood brain barrier.

15. A method according to claim 11, wherein a transdermal patch is used as a delivery method.

16. A method according to claim 11, wherein gum is used as a delivery method.

17. A method according to claim 11, wherein an inhaler is used as a delivery method.

18. A method according to claim 11, wherein a nasal spray is used as a delivery method.

20. A device according to claim 11, wherein said chemical include one or more of a set of chemical or chemicals known to decrease addiction behavior, or smoking behavior, or facilitate smoking cessation, or facilitate addiction cessation, or decrease signs and symptoms of nicotine and cigarette withdrawal, or other withdrawal, may be included in the device, including (but not limited to), clonidine, amfebutamone, mecamylamine, nortriptyline and moclobemide, dextrose, sugars, flavorants, vitamins, amino acids, minerals, other neutraceuticals, selegiline, pargyline, clorgyline, tranylcypromine, phenelzine, other inhibitors of MAO-A, other inhibitors of MAO-B, p-tyramine, serotonin, beta-phenylethylamine, or compounds related to these compounds.